Heterogeneity in Primary Colorectal Cancer and its Corresponding Metastases: A Potential Reason of EGFR-Targeted Therapy Failure?

被引：0
作者：
Li, Zhongqi [1 ]
Jin, Ketao [1 ,2 ]
Lan, Huanrong [3 ]
Teng, Lisong [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Surg, Zhuji, Zhejiang, Peoples R China
[3] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Gynecol & Obstet, Zhuji, Zhejiang, Peoples R China
来源：
HEPATO-GASTROENTEROLOGY | 2011年 / 58卷 / 106期
关键词：
Colorectal cancer; Epidermal growth factor receptor; Heterogeneity; Targeted therapy; GROWTH-FACTOR-RECEPTOR; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE-SURVIVAL; K-RAS MUTATIONS; KRAS MUTATIONS; P53; MUTATIONS; INTRATUMOR HETEROGENEITY; PIK3CA MUTATIONS; PRIMARY TUMORS; HUMAN BREAST;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Epidermal growth factor receptor (EGFR)targeted therapy represents an important approach in metastatic colorectal cancer (CRC) therapy. However, a number of CRC patients show intrinsic or acquired resistance to EGFR-targeted therapy. EGFR antibody therapy is established in CRC patients with wild-type KRAS. However, up to half of these patients do not respond to this therapy. This phenomenon implied some potential mechanisms of resistance to EGFR inhibitors might exist. One of the potential reasons to explain this phenomenon is heterogeneity of CRC. The heterogeneity of CRC has been well described at the morphological, molecular and genomic levels. This review discussed the potential relationship of heterogeneity, including intratumor heterogeneity of CRC and heterogeneity in primary CRC and its corresponding metastases, to EGFR-targeted therapy failure.
引用
收藏
页码：411 / 416
页数：6
相关论文
共 50 条
  • [31] Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
    Lorenzato, Annalisa
    Magri, Alessandro
    Matafora, Vittoria
    Audrito, Valentina
    Arcella, Pamela
    Lazzari, Luca
    Montone, Monica
    Lamba, Simona
    Deaglio, Silvia
    Siena, Salvatore
    Bertotti, Andrea
    Trusolino, Livio
    Bachi, Angela
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Arena, Sabrina
    [J]. CANCERS, 2020, 12 (03)
  • [32] Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases
    Agoston Emese Irma
    Baranyai Zsolt
    Dede Kristof
    Bodoky Gyorgy
    Kulka Janina
    Bursics Attila
    Harsanyi Laszlo
    Szasz, A. Marcell
    [J]. ORVOSI HETILAP, 2015, 156 (36) : 1460 - 1471
  • [33] EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
    Antonicelli, Alberto
    Cafarotti, Stefano
    Indini, Alice
    Galli, Alessio
    Russo, Andrea
    Cesario, Alfredo
    Lococo, Filippo Maria
    Russo, Patrizia
    Mainini, Alberto Franco
    Bonifati, Luca Giuseppe
    Nosotti, Mario
    Santambrogio, Luigi
    Margaritora, Stefano
    Granone, Pierluigi Maria
    Dutly, Andre Emanuel
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (03): : 320 - 330
  • [34] Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?
    Jin, Ketao
    He, Kuifeng
    Teng, Fei
    Han, Na
    Li, Guangliang
    Xu, Zhenzhen
    Teng, Lisong
    [J]. PERSONALIZED MEDICINE, 2011, 8 (02) : 175 - 182
  • [35] New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
    Bronte, Giuseppe
    Silvestris, Nicola
    Castiglia, Marta
    Galvano, Antonio
    Passiglia, Francesco
    Sortino, Giovanni
    Cicero, Giuseppe
    Rolfo, Christian
    Peeters, Marc
    Bazan, Viviana
    Fanale, Daniele
    Giordano, Antonio
    Russo, Antonio
    [J]. ONCOTARGET, 2015, 6 (28) : 24780 - 24796
  • [36] HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
    Sartore-Bianchi, Andrea
    Amatu, Alessio
    Porcu, Luca
    Ghezzi, Silvia
    Lonardi, Sara
    Leone, Francesco
    Bergamo, Francesca
    Fenocchio, Elisabetta
    Martinelli, Erika
    Borelli, Beatrice
    Tosi, Federica
    Racca, Patrizia
    Valtorta, Emanuele
    Bonoldi, Emanuela
    Martino, Cosimo
    Vaghi, Caterina
    Marrapese, Giovanna
    Ciardiello, Fortunato
    Zagonel, Vittorina
    Bardelli, Alberto
    Trusolino, Livio
    Torri, Valter
    Marsoni, Silvia
    Siena, Salvatore
    [J]. ONCOLOGIST, 2019, 24 (10) : 1395 - 1402
  • [37] Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
    Piawah, Sorbarikor
    Venook, Alan P.
    [J]. CANCER, 2019, 125 (23) : 4139 - 4147
  • [38] Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors
    Aprile, Giuseppe
    Casagrande, Mariaelena
    De Maglio, Giovanna
    Fontanella, Caterina
    Rihawi, Karim
    Bonotto, Marta
    Pisa, Federica E.
    Tuniz, Francesco
    Pizzolitto, Stefano
    Fasola, Gianpiero
    [J]. FUTURE ONCOLOGY, 2017, 13 (02) : 135 - 144
  • [39] Comparison of Lymphangiogenesis between Primary Colorectal Cancer and Corresponding Liver Metastases
    Schoppmann, Alexandra
    Tamandl, Dietmar
    Herberger, Beata
    Laengle, Friedrich
    Birner, Peter
    Geleff, Silvana
    Gruenberger, Thomas
    Schoppmann, Sebastian F.
    [J]. ANTICANCER RESEARCH, 2011, 31 (12) : 4605 - 4611
  • [40] Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
    Wang, Xiaojie
    Wu, Wenchuan
    Zheng, Zhifang
    Chi, Pan
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345